替吉奥联合阿帕替尼治疗晚期胰腺癌患者的临床疗效观察

Observation on clinical efficacy of Tegafur, gimeracil and oteracil potassium combined with apatinib in the treatment of advanced pancreatic cancer

目的探讨替吉奥联合阿帕替尼治疗晚期胰腺癌患者的临床疗效。方法 80例晚期胰腺癌患者,随机分为试验组和对照组,每组40例。对照组患者采取阿帕替尼治疗,试验组患者采用替吉奥联合阿帕替尼治疗。比较两组患者5、10、15、20个月无进展生存率。结果试验组患者5、10、15个月无进展生存率分别为47.5%、35.0%、25.0%,高于对照组的25.0%、15.0%、7.5%,差异有统计学意义(P<0.05);两组患者20个月无进展生存率比较差异无统计学意义(P>0.05)。结论对晚期胰腺癌患者使用替吉奥联合阿帕替尼治疗可以明显延长患者生命,值得在临床推广。

Objective To discuss the clinical efficacy of Tegafur, gimeracil and oteracil potassium combined with apatinib in the treatment of advanced pancreatic cancer. Methods A total of 80 patients with advanced pancreatic cancer were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with apatinib, and the experimental group was treated with Tegafur, gimeracil and oteracil potassium combined with apatinib. The progression-free survival rates at 5, 10, 15 and 20 months in both groups were compared. Results The experimental group had higher progression-free survival rates at 5, 10 and 15 months respectively as 47.5%, 35.0% and 25.0% than 25.0%, 15.0% and 7.5% in the control group, and the difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in progression-free survival rate at 20 months respectively（P〈0.05）. Conclusion Combination of Tegafur, gimeracil and oteracil potassium and apatinib can obviously prolong the life of patients with advanced pancreatic cancer, and it is worthy of clinical promotion.